Surveal Pharma: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
Surveal Pharma
Largest movements
- Cash -€1.3m
down €1.3m (-46.8%), from €2.7m to €1.4m
mainly Trade debts (-€926,260) and Receivables within one year (-€674,115)
- Receivables within one year +€674,115
up €674,115 (+35.5%), from €1.9m to €2.6m
of which Trade receivables: +€542,410
- Stocks and contracts +€237,336
up €237,336 (+31.6%), from €750,942 to €988,278
- Tangible fixed assets -€95,754
down €95,754 (-17.8%), from €537,374 to €441,620
of which Furniture and vehicles: -€66,513
- Trade debts -€926,260
down €926,260 (-23.5%), from €3.9m to €3.0m
- Profit (loss) carried forward +€431,161
up €431,161 (+32.4%), from €1.3m to €1.8m
- Short-term financial debts +€300,000
new in 2025: €300,000
- Tax, wage and social debts -€220,063
down €220,063 (-97.5%), from €225,766 to €5,703
of which Taxes: -€220,209
- Taxes -€981,402
down €981,402 (-82.7%), from €1.2m to €205,557
- Gross operating margin +€281,540
up €281,540 (+59.2%), from €475,451 to €756,991
- Financial income -€113,083
down €113,083 (-74.6%), from €151,556 to €38,473
- Financial charges -€58,892
down €58,892 (-40.3%), from €146,113 to €87,220
- Depreciation -€19,933
down €19,933 (-34.1%), from €58,499 to €38,566
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €5,919,332 | €5,472,110 | -€447,222 | -7.6% |
| Fixed assets | 21/28 | €537,729 | €441,975 | -€95,754 | -17.8% |
| Tangible fixed assets | 22/27 | €537,374 | €441,620 | -€95,754 | -17.8% |
| Land and buildings | 22 | €466,434 | €437,193 | -€29,240 | -6.3% |
| Furniture and vehicles | 24 | €70,940 | €4,427 | -€66,513 | -93.8% |
| Assets under construction and advance payments | 27 | €0 | - | = | |
| Financial fixed assets | 28 | €355 | €355 | = | 0.0% |
| Current assets | 29/58 | €5,381,603 | €5,030,135 | -€351,468 | -6.5% |
| Stocks and contracts in progress | 3 | €750,942 | €988,278 | +€237,336 | +31.6% |
| Stocks | 30/36 | €750,942 | €988,278 | +€237,336 | +31.6% |
| Amounts receivable within one year | 40/41 | €1,900,293 | €2,574,408 | +€674,115 | +35.5% |
| Trade receivables | 40 | €1,339,204 | €1,881,614 | +€542,410 | +40.5% |
| Other amounts receivable | 41 | €561,090 | €692,795 | +€131,705 | +23.5% |
| Current investments | 50/53 | €0 | - | = | |
| Cash at bank and in hand | 54/58 | €2,717,630 | €1,446,859 | -€1.3m | -46.8% |
| Deferred charges and accrued income | 490/1 | €12,738 | €20,590 | +€7,852 | +61.6% |
| Total equity and liabilities | 10/49 | €5,919,332 | €5,472,110 | -€447,222 | -7.6% |
| Equity | 10/15 | €1,386,059 | €1,817,220 | +€431,161 | +31.1% |
| Contributions | 10/11 | €50,000 | €50,000 | = | 0.0% |
| Reserves | 13 | €5,000 | €5,000 | = | 0.0% |
| Distributable reserves | 133 | €5,000 | €5,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | €1,331,059 | €1,762,220 | +€431,161 | +32.4% |
| Amounts payable | 17/49 | €4,533,273 | €3,654,890 | -€878,382 | -19.4% |
| Amounts payable after more than one year | 17 | €333,171 | €297,513 | -€35,658 | -10.7% |
| Financial debts | 170/4 | €333,171 | €297,513 | -€35,658 | -10.7% |
| Amounts payable within one year | 42/48 | €4,195,689 | €3,350,867 | -€844,823 | -20.1% |
| Current portion of amounts payable after more than one year | 42 | €34,156 | €35,658 | +€1,501 | +4.4% |
| Financial debts | 43 | - | €300,000 | +€300,000 | |
| Credit institutions | 430/8 | - | €300,000 | +€300,000 | |
| Trade debts | 44 | €3,935,767 | €3,009,507 | -€926,260 | -23.5% |
| Suppliers | 440/4 | €3,935,767 | €3,009,507 | -€926,260 | -23.5% |
| Taxes, remuneration and social security | 45 | €225,766 | €5,703 | -€220,063 | -97.5% |
| Taxes | 450/3 | €225,766 | €5,557 | -€220,209 | -97.5% |
| Remuneration and social security | 454/9 | €0 | €146 | +€146 | |
| Accrued charges and deferred income | 492/3 | €4,412 | €6,510 | +€2,098 | +47.6% |
| Remuneration, social security and pensions | 62 | €576 | €2,124 | +€1,548 | +269% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €58,499 | €38,566 | -€19,933 | -34.1% |
| Other operating charges | 640/8 | €15,284 | €30,836 | +€15,552 | +102% |
| Gross operating margin | 9900 | €475,451 | €756,991 | +€281,540 | +59.2% |
| Operating profit (loss) | 9901 | €401,092 | €685,465 | +€284,373 | +70.9% |
| Financial income | 75/76B | €151,556 | €38,473 | -€113,083 | -74.6% |
| Recurring financial income | 75 | €151,556 | €38,473 | -€113,083 | -74.6% |
| Financial charges | 65/66B | €146,113 | €87,220 | -€58,892 | -40.3% |
| Recurring financial charges | 65 | €146,113 | €87,220 | -€58,892 | -40.3% |
| Profit (loss) for the period before taxes | 9903 | €406,535 | €636,717 | +€230,182 | +56.6% |
| Income taxes | 67/77 | €1,186,958 | €205,557 | -€981,402 | -82.7% |
| Profit (loss) for the period | 9904 | -€780,423 | €431,161 | +€1.2m | |
| Profit (loss) for the period to be appropriated | 9905 | -€780,423 | €431,161 | +€1.2m |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 20 October 2026 via checked.be.